Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s
Digest more
MedPage Today on MSN
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
13don MSN
These Two Drugs Could Combine Forces to Treat Alzheimer’s—and They're Already On the Market
In a new study, scientists discovered two FDA-approved cancer drugs that could also be effective at combatting one well-known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback